medcelerator · clinician one-pager
New Weekly Shot for Protein Leak from IgA Kidney Disease
Trutakna (atacicept-vymj) — weekly under-the-skin shot to lower protein in the urine in adults with primary IgA nephropathy
FDA Approved · United States · September 11, 2026
Condition: IgA Nephropathy
Who this is for
This is for adults with primary IgA nephropathy who leak protein into the urine and may be candidates for labelled US Trutakna once-weekly home shots. It explains the accelerated FDA approval, the Week-36 urine-protein results from ORIGIN 3, infection and vaccine watchpoints, specialty-pharmacy shipping, and how to talk with a nephrology clinician — without treating confirmatory kidney-function results as already proven, a DIY import as a plan, or “approved” as the same thing as funded. Authorized is not funded.
Next clinical step
The US Food and Drug Administration (FDA) has approved this medicine. In the United States, ask your doctor or a specialist whether it suits you. They can write a prescription. Insurance or public drug plan coverage is not guaranteed.
Ways to access this treatment
United States · Prescription
US prescription (FDA-labelled)
https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-new-treatment-reduce-proteinuria-adults-primary-immunoglobulin-nephropathy
General resources for further research
ClinicalTrials.gov
US National Library of Medicine registry of clinical studies. Search by condition, drug, NCT number, and location. A listing is not enrolment, eligibility, or funding. Talk with the trial contact and a clinician before assuming a slot exists.
https://clinicaltrials.gov/
AI-produced discussion aid; not prescribing instructions. Approval does not establish coverage. Full article: https://medcelerator.com/articles/trutakna-atacicept